Newron Pharmaceuticals Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Operating Revenue	51.39	6.79	5.95	5.76	5.26	Upgrade
Other Revenue	-	2.26	0.14	-	-	Upgrade
Revenue	51.39	9.06	6.09	5.76	5.26	Upgrade
Revenue Growth (YoY)	467.41%	48.62%	5.76%	9.59%	-25.29%	Upgrade
Gross Profit	51.39	9.06	6.09	5.76	5.26	Upgrade
Selling, General & Admin	11.58	7.53	7.39	7.39	8.47	Upgrade
Research & Development	13.64	13.15	12.01	10.73	14.85	Upgrade
Operating Expenses	25.22	20.69	19.4	18.12	23.32	Upgrade
Operating Income	26.17	-11.63	-13.3	-12.36	-18.07	Upgrade
Interest Expense	-4.35	-4.17	-3.95	-2.92	-2.24	Upgrade
Interest & Investment Income	0.14	0.18	0.06	0.05	0.06	Upgrade
Currency Exchange Gain (Loss)	-0.1	-0.07	0.12	0.2	-0.17	Upgrade
Other Non Operating Income (Expenses)	-0.47	-0.51	-0.4	0.13	0.79	Upgrade
EBT Excluding Unusual Items	21.39	-16.2	-17.47	-14.88	-19.62	Upgrade
Pretax Income	21.39	-16.2	-17.47	-14.88	-19.62	Upgrade
Income Tax Expense	5.55	0.02	0.02	0.02	1.38	Upgrade
Net Income	15.84	-16.22	-17.49	-14.9	-21	Upgrade
Net Income to Common	15.84	-16.22	-17.49	-14.9	-21	Upgrade
Shares Outstanding (Basic)	19	18	18	18	18	Upgrade
Shares Outstanding (Diluted)	21	18	18	18	18	Upgrade
Shares Change (YoY)	15.30%	-	-	-	-	Upgrade
EPS (Basic)	0.85	-0.91	-0.98	-0.84	-1.18	Upgrade
EPS (Diluted)	0.77	-0.91	-0.98	-0.84	-1.18	Upgrade
Free Cash Flow	-17.63	-10.15	-11.11	-11.47	-15.62	Upgrade
Free Cash Flow Per Share	-0.86	-0.57	-0.62	-0.64	-0.88	Upgrade
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	Upgrade
Operating Margin	50.93%	-128.40%	-218.28%	-214.46%	-343.59%	Upgrade
Profit Margin	30.83%	-179.13%	-287.05%	-258.61%	-399.35%	Upgrade
Free Cash Flow Margin	-34.30%	-112.08%	-182.31%	-198.98%	-297.11%	Upgrade
EBITDA	26.2	-11.49	-13.27	-12.31	-17.99	Upgrade
EBITDA Margin	50.98%	-126.89%	-217.67%	-213.64%	-	Upgrade
D&A For EBITDA	0.02	0.14	0.04	0.05	0.07	Upgrade
EBIT	26.17	-11.63	-13.3	-12.36	-18.07	Upgrade
EBIT Margin	50.93%	-128.40%	-218.28%	-214.46%	-	Upgrade
Effective Tax Rate	25.95%	-	-	-	-	Upgrade
Revenue as Reported	51.39	9.06	6.09	5.76	5.26	Upgrade

Updated Sep 19, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.